6,678 trials
Mycoses
Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants
Hypogonadism
Primary: Percentage of Participants Achieving Normal Serum Testosterone Levels — 94.7 percentage of participants
Erectile Dysfunction
Primary: Per-subject Proportion of Sexual Attempts That Had an Erectogenic Effect Within Approximately 15 Minutes Following Dosing — 14.9; 25.9; 29.1 percentage of successes
Migraine Headache
Primary: Pain-free Status at 2 Hours Post-treatment — 42; 20; 20; 68 Participants — p=.312
Influenza, Human
Primary: Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) — 4.43; 4.38; 5.64; 5.64 Titers
Chronic Constipation
Primary: The Number of High-Amplitude Propagating Contractions (HAPC) — 8.7; 2.9 Number of HAPC with amplitude ≥100mmHg — p=0.012
Symptomatic Orthostatic Hypotension
Primary: Percent of Subjects Who Failed to Maintain a Response — 30.3; 44.1 percentage of participants — p=0.3145
Alzheimer's Disease
Primary: N-acetylaspartate — 1.35; 1.86; 1.58; 1.26 NAA/creatine Ratio
Perennial Allergic Rhinitis
Primary: Change From Baseline in Fatigue and Daytime Sleepiness at 2 Weeks — -0.64; 0.13; 0.46; -0.25 units on a scale
Chronic Migraine
Primary: Numeric Rating Scale (NRS) — 3.18; 3.78; 2.53; 3.51 units on a scale
Transplant; Failure, Kidney
Primary: Percent Change in Mean Fluorescence Index (MFI) of Donor Specific Antibodies (DSA) With Increasing Doses of Enteric-Coated Mycophenolate Sodium (EC-MPS) — 43.1 percent…
Chest Pain Syndrome
Primary: Length of Hospital Stay — 7.63; 8.20 Hours — p=0.79
Upper Respiratory Infection
Primary: Nasal Secretion Weights — 3.5; 4.2; 1.2; 2.6 grams
Metabolic Syndrome · Bipolar Depression · Insulin Resistance
Primary: Change in the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) Score — -16.5 units on a scale
Behavior · Anxiety
Primary: Verbal and Nonverbal Behavior in Therapy Session: Effects of Drug — 34; 34.8; 45.4; 46.0 Number of behaviors exhibited